medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Number 1

<< Back Next >>

Rev Invest Clin 2019; 71 (1)

Controversies and Limitations in the Diagnosis of Chronic Obstructive Pulmonary Disease

Reyes-García A, Torre-Bouscoulet L, Pérez-Padilla R

Language: English
References: 45
Page: 28-35
PDF size: 328.45 Kb.


ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality worldwide. While the cut-off point to define airflow obstruction has been controversial, it is widely accepted that the spirometry test is vital, as well as performing it after using a bronchodilator. The 6-second spirometry and the forced expiratory volume in 1 second/forced expiratory volume in 6 seconds (FEV1/FEV6) have demonstrated validity for defining obstruction, and it would be advisable to incorporate them in the definitions of obstruction. Another relevant issue is that spirometry with borderline obstruction can vary over time, changing to above or below the cut-off point. Thus, surveillance should be considered over time, repeating the spirometry to have a greater certainty in the diagnosis. The objective of this article was to conduct an in-depth review of the controversies in the diagnosis of COPD. During the past years, COPD definition has been updated in different times; however, it is now considered more as a complex syndrome with systemic participation, requiring a multidimensional assessment, and not only a spirometry.


REFERENCES

  1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Gold executive summary. Am J Respir Crit Care Med. 2017;195:557-82.

  2. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a systematic review and metaanalysis. BMJ Open. 2015;5:e008133.

  3. Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111-22.

  4. Eagan TM, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study. Eur Respir J. 2010;35:540-8.

  5. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483.

  6. Celli BR, Agustí A. COPD: time to improve its taxonomy? ERJ Open Res. 2018;4:00132-2017.

  7. Pérez-Padilla R, Fernández R, López Varela MV, et al. Airflow obstruction in never smokers in five Latin American cities: the PLATINO study. Arch Med Res. 2012;43:159-65.

  8. Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374:1811-21.

  9. Rodriguez-Roisin R, Han MK, Vestbo J, Wedzicha JA, Woodruff PG, Martinez FJ. Chronic respiratory symptoms with normal spirometry. A reliable clinical entity? Am J Respir Crit Care Med. 2017;195:17-22.

  10. Alcaide AB, Sanchez-Salcedo P, Bastarrika G, et al. Clinical features of smokers with radiological emphysema but without airway limitation. CHEST. 2017;151:358-65.

  11. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002;166:329-32.

  12. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med. 2011;3:619-27.

  13. Pérez-Padilla R, Wehrmeister FC, Celli BR, et al. Reliability of FEV1/FEV6 to diagnose airflow obstruction compared with FEV1/FVC: the PLATINO longitudinal study. PLoS One. 2013; 8:e67960.

  14. Jing J, Huang T, Cui W, Xu F, Shen H. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction?: a metaanalysis. Chest. 2009;135:991-8.

  15. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO. FEV6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med. 2000;162:917-9.

  16. Bhatt SP. Diagnosis of chronic obstructive pulmonary disease: breathing new life into an old debate. Ann Am Thorac Soc. 2018;15:163-5.

  17. van Dijk W, Tan W, Li P, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the can cold cohort. Ann Fam Med. 2015;13:41-8.

  18. Güder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort- study. Respir Res. 2012;13:13.

  19. Wollmer P, Engström G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: an outcome study. Respir Med. 2013;107:1460-2.

  20. Pérez-Padilla R, Hallal PC, Vázquez-García JC, et al. Impact of bronchodilator use on the prevalence of COPD in populationbased samples. COPD. 2007;4:113-20.

  21. Pérez-Padilla R, Wehrmeister FC, Montes de Oca M, et al. Instability in the COPD diagnosis upon repeat testing vary with the definition of COPD. PLoS One. 2015;10:e0121832.

  22. Choromańska A, Macura KJ. Role of computed tomography in quantitative assessment of emphysema. Pol J Radiol. 2012; 77:28-36.

  23. Milne S, King GG. Advanced imaging in COPD: insights into pulmonary pathophysiology. J Thorac Dis. 2014;6:1570-85.

  24. Lee YK, Oh YM, Lee JH, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung. 2008;186:157-65.

  25. Li J, Zhang H, Bai Y, et al. Diagnostic value of computed tomography in chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD J Chronic Obstruct Pulm Dis. 2012;9:563-70.

  26. Xie X, Jong PA de, Oudkerk M, et al. Morphological measurements in computed tomography correlate with airflow obstruction in chronic obstructive pulmonary disease: systematic review and meta-analysis. Eur Radiol. 2012;22:2085-93.

  27. Cotton DJ, Soparkar GR, Graham BL. Diffusing capacity in the clinical assessment of chronic airflow limitation. Med Clin. 1996; 80:549-64.

  28. Mohsenifar Z, Lee SM, Diaz P, et al. Single-breath diffusing capacity of the lung for carbon monoxide: a predictor of PaO2, maximum work rate, and walking distance in patients with emphysema. Chest. 2003;123:1394-400.

  29. Sundh J, Janson C, Lisspers K, Montgomery S, Ställberg B. Clinical COPD questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon Dis. 2012;7:833-42.

  30. Negro RW, Bonadiman L, Turco P. Sensitivity of the COPD assessment test (CAT questionnaire) investigated in a population of 681 consecutive patients referring to a lung clinic: the first Italian specific study. Multidiscip Respir Med. 2014;9:15.

  31. Anzueto A, Miravitlles M. Considerations for the correct diagnosis of COPD and its management with bronchodilators. Chest. 2018;154:242-8.

  32. Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis. 2017; 12:2291-305.

  33. Menezes AM, Pérez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366:1875-81.

  34. Haroon SM, Jordan RE, O’Beirne-Elliman J, Adab P. Effectiveness of case finding strategies for COPD in primary care: a systematic review and meta-analysis. NPJ Prim Care Respir Med. 2015; 25:15056.

  35. Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res. 2017;3:00117-2017.

  36. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 1005-12.

  37. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374:704-11.

  38. Casanova C, Aguirre-Jaíme A, Torres JP de, et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur Respir J. 2014;43:745-53.

  39. Pérez-Padilla R, Thirion-Romero I, Guzmán N. Underdiagnosis of chronic obstructive pulmonary disease: should smokers be offered routine spirometry tests? Expert Rev Respir Med. 2018; 12:83-5.

  40. Luize AP, Menezes AM, Pérez-Padilla R, et al. Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. NPJ Prim Care Respir Med. 2014;24:14075.

  41. Moreira GL, Gazzotti MR, Manzano BM, et al. Incidence of chronic obstructive pulmonary disease based on three spirometric diagnostic criteria in Sao Paulo, Brazil: a nine-year follow-up since the PLATINO prevalence study. Sao Paulo Med J. 2015; 133:245-51.

  42. Herrera AC, Montes de Oca M, López Varela MV, et al. COPD under diagnosis and misdiagnosis in a high-risk primary care population in four Latin American countries. A key to ehance disease diagnosis: the PUMA study. PLoS One. 2016;11: e0152266.

  43. López Varela MV, Montes de Oca M, Rey A, et al. Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: the PUMA study. Respirology. 2016;21:1227-34.

  44. Dirven JA, Tange HJ, Muris JW, van Haaren KM, Vink G, van Schayck OC. Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed-methods observational study. Prim Care Respir J. 2013;22:338-43.

  45. Tálamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest. 2007;131:60-7.




2020     |     www.medigraphic.com